Shire plc (SHPG): Xiidra Could Be Bigger Than Expected - Jefferies

September 19, 2016 8:36 AM EDT
Get Alerts SHPG Hot Sheet
Price: $176.39 --0%

Rating Summary:
    19 Buy, 4 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 10 | Down: 13 | New: 12
Trade SHPG Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Jefferies analyst, David Steinberg, reiterated his Buy rating on shares of Shire (NASDAQ: SHPG) after the second week of Xiidra being officially on the market. The posted 4205 TRxs, assuming a GtN discount of 30%, appears to be already generating annualized sales of $78M (if the product was not being offered for free). If they convert to full pay Rxs this will be a phenomenal result and the analyst believes there is good reason to think they will.

The analyst went on to say "While extremely early, SHPG could be positioned to make Xiidra its largest drug ever with peak US sales of $2B+". No change to the price target of $262.

For an analyst ratings summary and ratings history on Shire click here. For more ratings news on Shire click here.

Shares of Shire closed at $200.60 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Jefferies & Co

Add Your Comment